REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)

RecruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

April 17, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 23, 2028

Conditions
Alzheimer Disease
Interventions
DRUG

Brexpiprazole (Rexulti)

In general, for adults, start with taking 0.5 mg of brexpirazole at a time, once a day. Then the dose will be increased with an interval of at least one week to 1 mg at a time, once a day. If you have no problem with tolerability and do not show an adequate response, the dose may be increased to 2 mg at a time, once a day, but the increase should be made at intervals of at least one week.

Trial Locations (1)

540-0021

RECRUITING

Pharmacovigilance Department, Osaka

All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

NCT06875986 - REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease) | Biotech Hunter | Biotech Hunter